ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
Key facts
- Who runs it
- Australian and New Zealand Intensive Care Research Centre
- Where
- Australia, Belgium, Finland, Germany, Ireland, New Zealand, Saudi Arabia, Slovenia, and Switzerland41 sites in 9 countriesChoose a country to see its sites
- Trial code
- NCT04588311
- EudraCT 2020-003388-24
- U1111-1242-3694
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 2,500 people, planned
- Started
- 9 Nov 2020
- Expected to end
- 31 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Epoetin Alfa 40000 UNT/ML
- Sodium Chloride 0.9%
- Record updated
- 16 July 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Are ≥ 18 to ≤ 75 years of age
- Are < 24 hours since primary traumatic injury
- Are invasively mechanically ventilated
- Are expected to stay in the ICU ≥ 48 hours
- Have a haemoglobin not exceeding the upper limit of the applicable normal (ULN) reference range in clinical use at the treating institution
- Have informed consent from a legal surrogate according to local law
Who cannot take part
- Recent history of DVT, PE or other thromboembolic event (within previous 12 months or receiving concomitant anticoagulant treatment for this indication)
- Treatment with EPO in the last 30 days
- First dose of study drug unable to be given within 24 hours of primary injury
- A chronic hypercoagulable disorder, including known malignancy
- End stage renal failure (receives chronic dialysis)
- GCS = 3 and fixed dilated pupils
- Pregnancy or lactation or 3 months postpartum
- Expected to die imminently (< 24 hours)
- Known sensitivity to mammalian cell derived products
- Known contraindication to epoetin alfa
- Severe pre-existing physical or mental disability or severe co-morbidity that may interfere with the assessment of outcome
- The treating physician believes it is not in the best interest of the patient to be randomised to this trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in 9 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and severe disability at six months in critically ill trauma patients.
Read full original descriptionShow less
2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting to the ICU will be recruited into the study from participating study centres in Australia, New Zealand, Europe, and Saudi Arabia.
The 2 groups in the trial
- Erythropoietin (EPO)Existing treatment, for comparison
Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.
Treatment: Epoetin Alfa 40000 UNT/ML
- PlaceboPlacebo, for comparison
Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.
Treatment: Sodium Chloride 0.9%
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomised, Double-blind, Placebo-controlled Trial of Erythropoietin Alfa Versus Placebo in Mechanically Ventilated Critically Ill Patients Following Traumatic Injury
- Fit questions
- Built from NCT04588311, who can take part
- Record updated
- 16 July 2025